Deliver medicines that transform the lives of patients with neurodegenerative diseases
Founded in 2019, Vanqua Bio is a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases. Our novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to advance needed therapies. Our lead program targets glucocerebrosidase (GCase) as a potential treatment for Parkinson’s disease (PD) and all forms of Gaucher disease (GD). Additional programs address overactivation of the innate immune system in central and peripheral disorders, including Alzheimer’s disease.
I am humbled and inspired every day by the opportunity to make a profound difference in the lives of patients. It is my privilege to lead Vanqua Bio’s team of outstanding scientists on our journey to vanquish these devastating conditions.
– Jim Sullivan Ph.D., Vanqua Bio CEO
Vanqua Bio’s investors and partners are committed leaders in Parkinson’s disease, neuroscience research, and life–science investments.